Advanced searches left 3/3

Metastatic Neuroendocrine Tumor - Springer Nature

Summarized by Plex Scholar
Last Updated: 08 February 2022

* If you want to update the article please login/register

Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review

Introduction In this essay, we discuss a case of neuroendocrine neoplasm of unknown origin, which is a rare cause of ectopic Cushing's syndrome, which poses numerous challenges, as well as a literature review. Case report A 43-year-old male patient was seen with clinical signs similar to Cushing's syndrome and adrenocorticotropic hormone-dependent hypercortisolemia. Despite a suspicious lesion on pituitary MRI, the high-dose dexamethasone suppression test and bilateral inferior petrosal sinus sampling results were not compatible with Cushing's disease. In the thorax CT of the patient, who also had a history of COVID-19 disease, no tumorous opacities were found, but no tumors were present, but no tumor lesion was present. Multiple metastatic foci were established in mediastinal and hilar lymph nodes and the axial skeleton when 68Ga-SSTR PET/CT and 18FDG-PET/CT were conducted. Also when radiologically undetectable, the case in question highlighted the fact that atypical pulmonary carcinoid with a low proliferation index could result in visible metastases even though radiologically undetectable.

Source link: https://doi.org/10.1007/s42000-021-00316-z


Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

Purpose: More tumor reduction can be achieved by sequential therapy with [166Ho]-radioembolization following peptide receptor radionuclide therapy in patients with neuroendocrine tumor liver metastases, according to the authors' perspective. The aim of this research was to investigate hematotoxicity profiles, as well as the prognostic value of neutrophil-to-lymphocyte ratio and thrombocyte-to-lymphocyte ratios. Methods All patients who were prospective HEPAR PLuS study were included in this research. The prognostic value of NLR and TLR in response was determined by logistic regression to determine the prognostic value of NLR and TLR on response. Thirty-one patients were included in the toxicology study; thirty were included in the response analysis; thirty were not included in the response analysis. Patients with grade 3–4 lymphocyte toxicity developed in Ten patients. An increase in NLR and TLR at 3 weeks, relative to baseline, has risen in NLR and TLR at 3 weeks, compared to baseline, with excellent response at 3 months and 6 months. At a 3-weeks follow-up, the changes in NLR and TLR may be useful early predictors of response.

Source link: https://doi.org/10.1186/s13550-022-00880-4

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions